Hemodialysis Access Failure Clinical Trial
Official title:
Exploratory Research of PCSK9 Inhibitor on Patency of Autogenous Arteriovenous Fistula After Percutaneous Transluminal Angioplasty With Paclitaxel Releasing Balloon
Verified date | September 2023 |
Source | RenJi Hospital |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
Autologous arteriovenous fistula (AVF) is the preferred vascular pathway type for maintenance hemodialysis (MHD) patients. The K/DOQI guidelines suggest that the use of percutaneous transluminal angioplasty (PTA) as the primary treatment for AVF stenosis is reasonable. However, the durability of PTA is limited. In order to reduce the risk of dysfunction recurrence after the intervention, there have been reports in recent years that drug-coated balloons (DCB) are used in the treatment of vascular stenosis in hemodialysis. Multiple factors have limited the efficacy of DCB. Previous studies on the related factors of hemodialysis access stenosis showed that Dyslipidemia was significantly related to the short initial patency rate, and Dyslipidemia was an important predictor of secondary patency loss. Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors are a new type of lipid-lowering drug that can prevent vascular calcification. Previous studies have shown that PCSK9 inhibitors have good lipid-lowering effects in both MHD patients and nondialysis patients, and the use of PSK9 inhibitors at the same dose as nondialysis patients is safe in MHD patients. There are currently few studies on the use of paclitaxel-releasing balloon dilation combined with PCSK9 inhibitors to improve autologous internal fistula. Therefore, the investigators applied a prospective, randomized, and controlled study method to preliminarily explore the effect of paclitaxel releasing balloon combined with PCSK9 inhibitor on improving the postoperative patency rate of AVF and the safety of the combined application.
Status | Recruiting |
Enrollment | 40 |
Est. completion date | October 1, 2024 |
Est. primary completion date | September 6, 2024 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 17 Years to 76 Years |
Eligibility | Inclusion Criteria: 1. Agree to join this study and sign an informed consent form 2. Age = 18 years old and = 75 years old, regardless of gender 3. Maintenance hemodialysis patients using autologous arteriovenous fistula (AVF), with a dialysis frequency of three times a week 4. AVF venous stenosis: The local stenosis rate exceeds 50% of the normal diameter of nearby blood vessels and is accompanied by at least one of the following conditions: 1. The natural blood flow of the internal fistula is less than 500ml/min or has decreased by more than 25% compared to the previous examination result 2. Unable to meet the required blood flow for dialysis prescription (blood flow<200ml/min, and cannot be corrected after adjusting the puncture needle position) 3. Decreased arterial pressure or increased venous pressure during dialysis (monitoring arterial pressure<-120mmHg for more than 2 consecutive times or monitoring venous pressure>120mmHg while maintaining 200ml/min blood flow) 4. Difficulty in puncture: A qualified nurse who has difficulty puncturing for 3 consecutive days of hemodialysis (blood can only be drawn out after more than two punctures) 5. Decreased dialysis adequacy [arteriovenous fistula recirculation rate (RA)>10%, or an increase of more than 25% compared to the previous examination result] [RA=(SA-A)/(SA-V) * 100, dialysis to 1 hour: SA=blood flow adjusted to 20ml/min, ultrafiltration and dialysate flow stopped, after 2 minutes, artery Blood urea nitrogen concentration A=artery Blood urea nitrogen concentration V=vein Blood urea nitrogen concentration] 6. Abnormal signs of fistula. 5. Patients with primary Hypercholesterolemia [LDL-C = 130 mg/dl (= 3.4 mmol/L), and/or non-HDL-C= 160 mg/dl (= 4.1 mmol/L)] or combine cardiovascular disease or assess patients with a high risk of cardiovascular disease Exclusion Criteria: 1. MHD with AVG 2. Breastfeeding or Pregnant Women 3. Patients with central venous reflux obstruction 4. Patients with AVF feeding artery disease 5. Patients with severe Hypotension (systolic blood pressure<90mmHg or diastolic blood pressure<60mmHg, at least three times within one month before signing the informed consent) 6. Left ventricular Ejection fraction less than 30% or hemodynamic instability 7. Patients receiving immunotherapy or suspected/confirmed Vasculitis 8. Patients with coagulation dysfunction or a history of Thrombocytopenic purpura 9. Patients with vascular access infections or systemic active infections 10. Patients who are known to be allergic to PCSK9 inhibitors or paclitaxel 11. Patient's life expectancy is less than 12 months 12. Patients who are planning kidney transplantation or switching to Peritoneal dialysis 13. Patients participating in other intervention studies 14. The researcher judged that the subject's condition was not suitable for participation in this study |
Country | Name | City | State |
---|---|---|---|
China | Yuanyuan Xie | Shanghai | Pudong |
Lead Sponsor | Collaborator |
---|---|
RenJi Hospital |
China,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Value of vessel diameter | ultrasonic measurement | 24 week, 48 week | |
Primary | Value of volume of blood flow | ultrasonic measurement | 24 week, 48 week | |
Primary | Value of peak systolic velocity ratio(PSVR) | ultrasonic measurement | 24 week, 48 week | |
Primary | Incidence of Re intervention of fistula | Event recording | 48 week | |
Secondary | Endometrium | Ultrasonic measurement of changes in thickness of vascular intima , expressed in millimeters | 24 week, 48 week | |
Secondary | RA | Arteriovenous fistula recirculation rate | 24 week, 48 week | |
Secondary | BTM | Blood temperature monitoring, testing of specific modules of the hemodialysis machine. Expressed as a percentage. | 24 week, 48 week | |
Secondary | Adequacy of dialysis | spKT/V | 24 week, 48 week | |
Secondary | Blood routine | Concentration of hemoglobin, white blood cell count, platelet | 12 week, 24 week, 48 week | |
Secondary | liver function | Concentration of GPT, GOT | 12 week, 24 week, 48 week | |
Secondary | Concentration of blood sugar | 12 week, 24 week, 48 week | ||
Secondary | Concentration of CRP | 12 week, 24 week, 48 week | ||
Secondary | blood lipids | Concentration of cholesterol, triglyceride, LDL-c, HDL | 12 week, 24 week, 48 week |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT03952819 -
The Effects of Hemodialysis on Serum Sclerostin Levels
|
||
Active, not recruiting |
NCT04054128 -
Bicarbonate vs Heparin Catheter Lock in Chronic Hemodialysis Patients
|
Phase 4 | |
Active, not recruiting |
NCT04376567 -
Outcomes for One-stage and Two-stage Brachial Basilic Arteriovenous Fistulas
|
N/A | |
Completed |
NCT03627884 -
Outcomes of the Use of Sodium Bicarbonate (8.4%) Solution as a Catheter Lock Solution to Prevent Hemodialysis Catheter Loss Due to Lumen Clot Formation
|
Phase 4 | |
Recruiting |
NCT06001827 -
SAVE-FistulaS: the SelfWrap-Assisted ArterioVEnous Fistulas Study
|
N/A | |
Recruiting |
NCT04285073 -
Prospective, Multicenter, Non-randomized, Single Arm Clinical Trial to Evaluate the Safety and Efficacy of e-PTFE Grafts Inner Surface-treated With Paclitaxel as an Access for Hemodialysis in Patients With End-stage Renal Disease.
|
N/A | |
Recruiting |
NCT05906550 -
Flow Dysfunction of Hemodialysis Vascular Access
|
N/A | |
Not yet recruiting |
NCT04098159 -
Role of Regular Surveillance on Maintenance of Patency of an Arteriovenous Access
|
N/A | |
Terminated |
NCT05228132 -
The Pristine Post-Market Study
|
N/A | |
Recruiting |
NCT03365089 -
Collateral Ligation in Failing Fistulas
|
N/A | |
Recruiting |
NCT04489849 -
Apixaban for Prevention of Post-angioplasty Thrombosis of Hemodialysis Vascular Access
|
Phase 4 | |
Recruiting |
NCT03140345 -
Integrative HD Vascular Access Assessment
|
N/A | |
Enrolling by invitation |
NCT04381754 -
Use of Implanting the Biotronik Passeo-18 Lux Drug Coated Balloon to Treat Failing Haemodialysis Arteriovenous Fistulas and Grafts.
|
||
Completed |
NCT03988270 -
Prefistula Forearm Exercise in Pts Requiring Chronic HD Therapy
|
N/A | |
Recruiting |
NCT04502160 -
The Northern Ireland Haemodialysis Vascular Access Database
|
||
Active, not recruiting |
NCT05418816 -
SelfWrap-Assisted Arteriovenous Fistulas
|
N/A | |
Completed |
NCT04263116 -
Balloon-Assisted Maturation of Autogenous Arteriovenous Fistulae
|
N/A | |
Completed |
NCT05081648 -
Must Cannulation Technique of Vascular Access in Patients Undergoing Haemodialysis: Contributions for a Safe Nursing Intervention
|
N/A | |
Recruiting |
NCT06454396 -
Effectiveness and Health Economics of Endoluminal Treatment of Autologous Arteriovenous Endovascular Fistula Failure
|
||
Not yet recruiting |
NCT05096416 -
Three-dimensional (3D) Printed Hemodialysis Vascular Model
|
N/A |